NHS finance leaders do not need another AI pitch. They need a disciplined way to decide whether a technology can release value within the financial rules they are already being held to.

A familiar line turns up whenever medicines productivity is discussed in the NHS: generic prescribing has already been done. The easy gains have gone. We need to look elsewhere.

If strategic commissioning is going to mean anything in 2026/27, it has to change how integrated care boards manage medicines value.

The NHS does not lack medicines dashboards. It lacks enough tools that turn those signals into action.That distinction matters because many digital programmes in medicines still behave as though visibility is the scarce resource

If NHS leaders are looking for a near-term medicines productivity play with a strong policy tailwind, best-value biological medicines should be near the top of the list.